189 related articles for article (PubMed ID: 17178785)
1. Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU.
Lee VT; Pukatzki S; Sato H; Kikawada E; Kazimirova AA; Huang J; Li X; Arm JP; Frank DW; Lory S
Infect Immun; 2007 Mar; 75(3):1089-98. PubMed ID: 17178785
[TBL] [Abstract][Full Text] [Related]
2. In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors.
Phillips RM; Six DA; Dennis EA; Ghosh P
J Biol Chem; 2003 Oct; 278(42):41326-32. PubMed ID: 12915403
[TBL] [Abstract][Full Text] [Related]
3. ExoU is a potent intracellular phospholipase.
Sato H; Frank DW
Mol Microbiol; 2004 Sep; 53(5):1279-90. PubMed ID: 15387809
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread.
Allewelt M; Coleman FT; Grout M; Priebe GP; Pier GB
Infect Immun; 2000 Jul; 68(7):3998-4004. PubMed ID: 10858214
[TBL] [Abstract][Full Text] [Related]
5. A sensitive fluorescence-based assay for the detection of ExoU-mediated PLA(2) activity.
Benson MA; Schmalzer KM; Frank DW
Clin Chim Acta; 2010 Feb; 411(3-4):190-7. PubMed ID: 19900431
[TBL] [Abstract][Full Text] [Related]
6. Mutation of the phospholipase catalytic domain of the Pseudomonas aeruginosa cytotoxin ExoU abolishes colonization promoting activity and reduces corneal disease severity.
Tam C; Lewis SE; Li WY; Lee E; Evans DJ; Fleiszig SM
Exp Eye Res; 2007 Dec; 85(6):799-805. PubMed ID: 17905228
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of SpcU, a chaperone required for efficient secretion of the ExoU cytotoxin.
Finck-Barbançon V; Yahr TL; Frank DW
J Bacteriol; 1998 Dec; 180(23):6224-31. PubMed ID: 9829931
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU.
Pankhaniya RR; Tamura M; Allmond LR; Moriyama K; Ajayi T; Wiener-Kronish JP; Sawa T
Crit Care Med; 2004 Nov; 32(11):2293-9. PubMed ID: 15640644
[TBL] [Abstract][Full Text] [Related]
9. Identification of superoxide dismutase as a cofactor for the pseudomonas type III toxin, ExoU.
Sato H; Feix JB; Frank DW
Biochemistry; 2006 Aug; 45(34):10368-75. PubMed ID: 16922513
[TBL] [Abstract][Full Text] [Related]
10. Lysophospholipase A activity of Pseudomonas aeruginosa type III secretory toxin ExoU.
Tamura M; Ajayi T; Allmond LR; Moriyama K; Wiener-Kronish JP; Sawa T
Biochem Biophys Res Commun; 2004 Apr; 316(2):323-31. PubMed ID: 15020221
[TBL] [Abstract][Full Text] [Related]
11. The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU.
Sato H; Frank DW; Hillard CJ; Feix JB; Pankhaniya RR; Moriyama K; Finck-Barbançon V; Buchaklian A; Lei M; Long RM; Wiener-Kronish J; Sawa T
EMBO J; 2003 Jun; 22(12):2959-69. PubMed ID: 12805211
[TBL] [Abstract][Full Text] [Related]
12. Eicosanoid-mediated proinflammatory activity of Pseudomonas aeruginosa ExoU.
Saliba AM; Nascimento DO; Silva MC; Assis MC; Gayer CR; Raymond B; Coelho MG; Marques EA; Touqui L; Albano RM; Lopes UG; Paiva DD; Bozza PT; Plotkowski MC
Cell Microbiol; 2005 Dec; 7(12):1811-22. PubMed ID: 16309466
[TBL] [Abstract][Full Text] [Related]
13. Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review.
Sawa T; Shimizu M; Moriyama K; Wiener-Kronish JP
Crit Care; 2014 Dec; 18(6):668. PubMed ID: 25672496
[TBL] [Abstract][Full Text] [Related]
14. Multiple domains are required for the toxic activity of Pseudomonas aeruginosa ExoU.
Finck-Barbançon V; Frank DW
J Bacteriol; 2001 Jul; 183(14):4330-44. PubMed ID: 11418575
[TBL] [Abstract][Full Text] [Related]
15. Identification of the major ubiquitin-binding domain of the Pseudomonas aeruginosa ExoU A2 phospholipase.
Anderson DM; Feix JB; Monroe AL; Peterson FC; Volkman BF; Haas AL; Frank DW
J Biol Chem; 2013 Sep; 288(37):26741-52. PubMed ID: 23908356
[TBL] [Abstract][Full Text] [Related]
16. Interactions of the effector ExoU from
Springer TI; Reid TE; Gies SL; Feix JB
J Biol Chem; 2019 Dec; 294(50):19012-19021. PubMed ID: 31662432
[No Abstract] [Full Text] [Related]
17. Phosphatidylinositol 4,5-Bisphosphate-Dependent Oligomerization of the Pseudomonas aeruginosa Cytotoxin ExoU.
Zhang A; Veesenmeyer JL; Hauser AR
Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993456
[TBL] [Abstract][Full Text] [Related]
18. A pipeline to evaluate inhibitors of the Pseudomonas aeruginosa exotoxin U.
Foulkes DM; McLean K; Zheng Y; Sarsby J; Haneef AS; Fernig DG; Winstanley C; Berry N; Kaye SB
Biochem J; 2021 Feb; 478(3):647-668. PubMed ID: 33459338
[TBL] [Abstract][Full Text] [Related]
19. Intoxication of host cells by the T3SS phospholipase ExoU: PI(4,5)P2-associated, cytoskeletal collapse and late phase membrane blebbing.
Sato H; Frank DW
PLoS One; 2014; 9(7):e103127. PubMed ID: 25061861
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on the
Hardy KS; Tessmer MH; Frank DW; Audia JP
Toxins (Basel); 2021 Dec; 13(12):. PubMed ID: 34941717
[No Abstract] [Full Text] [Related]
[Next] [New Search]
